GDF-15 and P-Tau217: The Biomarkers That Warn You Before You Feel Anything
New biomarker research is shifting the question from 'what's wrong?' to 'what's coming?' GDF-15 as a cellular stress signal and p-tau217 for pre-symptomatic Alzheimer's risk represent a new category of early detection — but their limitations matter as much as their promise.
GDF-15 and P-tau217: The Biomarkers That Signal Breakdown Before You Feel It
Two biomarkers — GDF-15 for cellular stress and P-tau217 for Alzheimer's risk — can flag physiological strain years before symptoms appear. Here's what they measure, what trends reveal, and why a single reading misses the point.
Peter Attia Episode 404: Why the Neurotransmitter Model of Mental Health Is Incomplete
Dr. Linus Abrams argues that psychiatry's focus on symptom reduction through medication overlooks the hormonal, metabolic, and inflammatory drivers of mental health. The implications for how practitioners and patients think about mental wellbeing are significant.
Peter Attia's Framework for Environmental Threats to Longevity: Air, Noise, and Light
AMA #87 applies Attia's 80/20 principle to chronic environmental exposures — PM2.5, noise, and artificial light — and which interventions actually move the longevity needle.
GARM's Klotho Longevity Residency Brought 22 Participants to Honduras. Here's What They're Testing.
A four-day longevity residency at the Kimpton Grand Roatán included a proprietary Klotho intervention, blood sampling before and after, and researchers from MIT and Harvard. GARM is betting that Klotho is the next longevity biomarker to watch.
Beacon Biosignals: AI Sleep Staging Is Moving Out of the Lab
Beacon Biosignals presented clinical validation data for its AI sleep staging algorithms at SLEEP 2026. What their EEG foundation model means for where consumer sleep tech is headed.
Why Smart People Believe Bad Health Advice: The Cognitive Bias Map
Intelligence doesn't protect against health misinformation — it often amplifies it. Here's the framework for recognizing which cognitive traps are most likely to corrupt your health decision-making.
APOE2: The Gene That Supercharges Your Neurons' DNA Repair
Buck Institute research links APOE2 to measurably lower neuronal senescence and stronger DNA repair — the mechanism behind why APOE2 carriers resist Alzheimer's disease.
At-Home Finger-Prick Test Hits 86% Accuracy for Alzheimer's
Nature Medicine validated at-home p-tau217 finger-prick sampling at 86% accuracy. Here's what it means for early Alzheimer's detection.
Inbrain's Graphene Brain Interface: First Human Trial Results Signal a New Class of Neural Device
Inbrain's graphene cortical interface completed its first 8-patient human trial with no device-related adverse events — a safety milestone for a neural recording technology designed to be thinner and more biocompatible than conventional silicon.
Cataracts and Dementia Risk: The Surprisingly Simple Brain-Protection Lever
A meta-analysis of 558,276 participants finds cataract surgery associated with 25% lower dementia risk. Vision correction may be one of the most accessible cognitive interventions in aging.
Your Smartwatch May Be Able to Predict Cognitive Decline — Before You Notice It
A University of Geneva study using 88 participants over 10 months found AI can predict fluctuations in brain health from passive wearable data with just 12.5% average error.
Obicetrapib: The Drug Targeting Both Heart Disease and Alzheimer's at Once
A CETP inhibitor in late-stage trials cut LDL by up to 50% while reducing Alzheimer's biomarkers. The BROADWAY trial data may represent a new category of longevity drug.
One Man's Alzheimer's Mutation Isn't Causing Dementia. Heat Shock Proteins May Be Why.
A 75-year-old with a dominant Alzheimer's mutation remains cognitively healthy. Heat shock proteins may explain why — and what it means for brain longevity research.
Sensory Stimulation Architecture: Cognito's $105M Cognitive Longevity Play
Cognito Therapeutics secures $105M to advance its non-invasive sensory stimulation therapy, marking a shift in Alzheimer's treatment architecture from chemical to electrical intervention.
Gamma-Band Modulation: The Hardware-Software Convergence in Cognitive Longevity
Analyzing the Spectris platform's use of sensory-driven gamma oscillations to preserve neural architecture and cognitive function.
The Longevity Protocol: Benchmarking Strength and VO2 Max for Cognitive Resilience
Analyzing the architectural requirements for lifelong physical and cognitive performance through the lens of recent longevity benchmarks.
The Klotho Protocol: Architecting the Future of Cognitive Resilience
Klothea initiates the first longevity-focused human trial of mRNA-based klotho therapy, marking a shift from theoretical anti-aging to clinical bio-architecture.